Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-05221304 (NSC-170984) is an orally active, liver-targeted inhibitor of acetyl-CoA carboxylase (ACC), a rate-limiting enzymes for fatty acid synthesis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 143.00 | |
5 mg | In stock | $ 293.00 | |
10 mg | In stock | $ 441.00 | |
25 mg | In stock | $ 767.00 | |
50 mg | In stock | $ 996.00 | |
100 mg | In stock | $ 1,450.00 | |
200 mg | In stock | $ 1,950.00 | |
500 mg | In stock | $ 2,890.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 447.00 |
Description | PF-05221304 (NSC-170984) is an orally active, liver-targeted inhibitor of acetyl-CoA carboxylase (ACC), a rate-limiting enzymes for fatty acid synthesis. |
In vitro | PF-05221304 blocked polarization of human T cells to proinflammatory but not anti-inflammatory T cells, and suppressed activation of primary human stellate cells to myofibroblasts in vitro, showing direct effects on inflammation and fibrogenesis[1]. |
In vivo | PF-05221304 reduced markers of inflammation and fibrosis in the diethylnitrosamine chemical-induced liver injury model and the choline-deficient, high-fat-fed rat model[1]. |
Synonyms | STAT5 Inhibitor III, NSC 170984, R 6238,, Clesacostat |
Molecular Weight | 502.56 |
Formula | C28H30N4O5 |
CAS No. | 1370448-25-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 95mg/ml(189.03mM)
ethanol: 5mg/ml(9.95mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PF-05221304 1370448-25-1 Metabolism Acetyl-CoA Carboxylase STAT5 Inhibitor III NSC 170984 PF 05221304 PF05221304 NSC170984 R 6238, NSC-170984 Clesacostat inhibitor inhibit